Telavancin Blood and Cerebrospinal Fluid Concentrations in Patients With Subarachnoid Hemorrhage

Launched by AARON COOK · Oct 31, 2023

Keywords

ClinConnect Summary

This clinical trial is studying how well a medication called telavancin can reach the central nervous system (CNS) in patients who have experienced a type of brain bleed known as spontaneous subarachnoid hemorrhage (SAH). The researchers want to see how much of the medication can be found in the cerebrospinal fluid (CSF), which is the fluid surrounding the brain and spinal cord. This is important because patients with SAH often need to stay in the intensive care unit (ICU) for a long time and may have a device to drain CSF to prevent complications.

To participate in this trial, individuals must be between 18 and 65 years old, have had a spontaneous SAH, and have a specific score indicating the severity of their condition. Participants will receive telavancin for three days and will have blood and CSF samples taken to measure how much of the medication is present. It's important to note that those with certain health conditions, like severe kidney problems or a history of allergic reactions to similar medications, will not be eligible. This trial is currently recruiting patients, and it aims to improve treatment options for those affected by this serious condition.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Spontaneous subarachnoid hemorrhage
• • Hunt-Hess score of 1-4
• • Actively draining ventriculostomy
• Exclusion Criteria:
• • history of hypersensitivity to telavancin or similar agents
• • reduced renal function (estimated creatinine clearance \< 50/ml) at the time of consent
• • severe anemia (hemoglobin \< 7gm/dl)
• • vulnerable population (pregnant, prisoner)